23andMe Holding Co.
ME US
ME US23andMe Holding Co.
United States Composite0.44
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Ms. Anne Wojcicki
- Full Time Employees
- 769
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Address
- 349 Oyster Point Boulevard South San Francisco CA United States 94080
- IPO Date
- Nov 23, 2020
- Website
- www.23andme.com
- Business
- 23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
Company News
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
Canada, UK launched joint probe into 23andMe data breach, says Canada
23andMe Launches New Genetic Report on Bipolar Disorder
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Q4 2024 23andMe Holding Co. Earnings Call
23andMe Holding Co (ME) Q4 2024 Earnings Call Transcript Highlights: Navigating Revenue Declines and Strategic Shifts
Q4 2024 23andMe Holding Co. Earnings Call Transcript
23andMe Holding (ME) Buy Rating Justified by Strong Revenue and Strategic Developments
23andMe, citing strategic alternatives review, not providing fiscal 2025 guidance
23andMe (ME) Q4 FY24 Earnings: Revenue Beats Estimates Despite 31% YoY Decline, EPS Misses Expectations
23andMe Gains as Revenue Beats Despite Flagging DNA Sales
23andMe GAAP EPS of -$0.43, revenue of $64.03M beats by $2.58M
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health Now Offers Prescription ED Medication STENDRA? Through Collaboration with Petros Pharmaceuticals
Struggling 23andMe Granted Extension to Revive Stock Price
Struggling 23andMe Granted Extension to Revive Stock Price